In-vitro sensitivity of Pakistani Leishmania tropica field isolate against buparvaquone in comparison to standard anti-leishmanial drugs.

[1]  Dildar Hussain,et al.  Cutaneous leishmaniasis in Sadda, Kurram Agency, Pakistan , 2017 .

[2]  P. Devarajan,et al.  Buparvaquone loaded solid lipid nanoparticles for targeted delivery in theleriosis , 2014, Journal of pharmacy & bioallied sciences.

[3]  R. R. Yadav,et al.  Discovery of 3,3'-diindolylmethanes as potent antileishmanial agents. , 2013, European journal of medicinal chemistry.

[4]  J. Berman,et al.  Drug discovery algorithm for cutaneous leishmaniasis. , 2013, The American journal of tropical medicine and hygiene.

[5]  S. Croft,et al.  The Relevance of Susceptibility Tests, Breakpoints, and Markers , 2013 .

[6]  E. Chatelain,et al.  Visceral leishmaniasis treatment: What do we have, what do we need and how to deliver it? , 2012, International journal for parasitology. Drugs and drug resistance.

[7]  Ravinder,et al.  Development of Luciferase Expressing Leishmania donovani Axenic Amastigotes as Primary Model for In Vitro Screening of Antileishmanial Compounds , 2012, Current Microbiology.

[8]  N. Baddour,et al.  Miltefosine for Old World cutaneous leishmaniasis: An experimental study on Leishmania major infected mice , 2012 .

[9]  D. Andreu,et al.  Defeating Leishmania resistance to miltefosine (hexadecylphosphocholine) by peptide-mediated drug smuggling: a proof of mechanism for trypanosomatid chemotherapy. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[10]  S. Rault,et al.  Discovery of a new antileishmanial hit in 8-nitroquinoline series. , 2012, European journal of medicinal chemistry.

[11]  M. Ouellette,et al.  Discovery of factors linked to antimony resistance in Leishmania panamensis through differential proteome analysis. , 2012, Molecular and biochemical parasitology.

[12]  Nisha Singh,et al.  Leishmaniasis: current status of available drugs and new potential drug targets. , 2012, Asian Pacific journal of tropical medicine.

[13]  A. Rabello,et al.  Validation of quantitative real-time PCR for the in vitro assessment of antileishmanial drug activity. , 2012, Experimental parasitology.

[14]  J. Cano,et al.  Leishmaniasis Worldwide and Global Estimates of Its Incidence , 2012, PloS one.

[15]  M. Eissa,et al.  Giardia lamblia: a new target for miltefosine. , 2012, International journal for parasitology.

[16]  Wenhua Song,et al.  Study on cytotoxicity and structure-activity relationship of HL-7702 cell exposed to naphthoquinones. , 2012, Environmental toxicology and pharmacology.

[17]  A. Tempone,et al.  Effectiveness of liposomal buparvaquone in an experimental hamster model of Leishmania (L.) infantum chagasi. , 2012, Experimental parasitology.

[18]  D. Singh,et al.  Mechanism of Amphotericin B Resistance in Clinical Isolates of Leishmania donovani , 2011, Antimicrobial Agents and Chemotherapy.

[19]  S. Kaur,et al.  Vaccine candidates for leishmaniasis: a review. , 2011, International immunopharmacology.

[20]  A. Khamesipour,et al.  The effect of verapamil on in vitro susceptibility of promastigote and amastigote stages of Leishmania tropica to meglumine antimoniate , 2011, Parasitology Research.

[21]  B. Oury,et al.  Leishmania antimony resistance: what we know what we can learn from the field , 2011, Parasitology Research.

[22]  G. Lewin,et al.  In vitro antileishmanial properties of new flavonoids against Leishmania donovani , 2011 .

[23]  M. Arkin,et al.  A Screen against Leishmania Intracellular Amastigotes: Comparison to a Promastigote Screen and Identification of a Host Cell-Specific Hit , 2011, PLoS neglected tropical diseases.

[24]  M. Martins,et al.  Systematic review of the adverse effects of cutaneous leishmaniasis treatment in the New World. , 2011, Acta tropica.

[25]  D. Muñoz,et al.  Leishmania tarentolae: utility as an in vitro model for screening of antileishmanial agents. , 2010, Experimental parasitology.

[26]  H. Maltezou,et al.  Leishmaniasis, an emerging infection in travelers. , 2010, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[27]  Suman Gupta,et al.  Synthesis of 2‐(Pyrimidin‐2‐yl)‐1‐phenyl‐2,3,4,9‐tetrahydro‐1H‐β‐carbolines as Antileishmanial Agents. , 2010 .

[28]  V. Yardley,et al.  Antileishmanial and Antitrypanosomal Activities of the 8-Aminoquinoline Tafenoquine , 2010, Antimicrobial Agents and Chemotherapy.

[29]  Suman Gupta,et al.  Synthesis of 2-(pyrimidin-2-yl)-1-phenyl-2,3,4,9-tetrahydro-1H-beta-carbolines as antileishmanial agents. , 2010, European journal of medicinal chemistry.

[30]  R. Lavanya,et al.  In-vitro Antioxidant Activity of Methanolic Extract in Leaves of Anisomeles malabarica Linn , 2010 .

[31]  M. Sauvain,et al.  Ta'ta', Huayani: perception of leishmaniasis and evaluation of medicinal plants used by the Chayahuita in Peru. Part II. , 2009, Journal of ethnopharmacology.

[32]  S. Tyring,et al.  Tropical dermatology: Tropical diseases caused by protozoa. , 2009, Journal of the American Academy of Dermatology.

[33]  S. Croft,et al.  Optimization and validation of RP-HPLC-UV method with solid-phase extraction for determination of buparvaquone in human and rabbit plasma: application to pharmacokinetic study. , 2008, Biomedical chromatography : BMC.

[34]  F. Tuon,et al.  Mucosal leishmaniasis . Current scenario and prospects for treatment. , 2008, Acta tropica.

[35]  S. Croft,et al.  Inactivation of the miltefosine transporter, LdMT, causes miltefosine resistance that is conferred to the amastigote stage of Leishmania donovani and persists in vivo. , 2007, International journal of antimicrobial agents.

[36]  M. Ouellette,et al.  Glucantime-resistant Leishmania tropica isolated from Iranian patients with cutaneous leishmaniasis are sensitive to alternative antileishmania drugs , 2007, Parasitology Research.

[37]  S. Croft,et al.  Development and validation of RP-HPLC-UV method for simultaneous determination of buparvaquone, atenolol, propranolol, quinidine and verapamil: a tool for the standardization of rat in situ intestinal permeability studies. , 2007, Journal of pharmaceutical and biomedical analysis.

[38]  S. Croft,et al.  Miltefosine--discovery of the antileishmanial activity of phospholipid derivatives. , 2006, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[39]  J. Dujardin,et al.  Molecular Diagnosis of Leishmaniasis: Current Status and Future Applications , 2006, Journal of Clinical Microbiology.

[40]  V. Yardley,et al.  American tegumentary leishmaniasis: Is antimonial treatment outcome related to parasite drug susceptibility? , 2006, The Journal of infectious diseases.

[41]  V. Yardley,et al.  Current scenario of drug development for leishmaniasis. , 2006, The Indian journal of medical research.

[42]  S. Croft,et al.  Mechanisms of experimental resistance of Leishmania to miltefosine: Implications for clinical use. , 2006, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[43]  S. Croft,et al.  In Vitro and In Vivo Interactions between Miltefosine and Other Antileishmanial Drugs , 2006, Antimicrobial Agents and Chemotherapy.

[44]  P. Desjeux.  Leishmaniasis: current situation and new perspectives. , 2004, Comparative immunology, microbiology and infectious diseases.

[45]  S. Croft,et al.  Synthesis, in vitro evaluation, and antileishmanial activity of water-soluble prodrugs of buparvaquone. , 2004, Journal of medicinal chemistry.

[46]  S. Croft,et al.  Miltefosine (Impavido): the first oral treatment against leishmaniasis , 2004, Medical Microbiology and Immunology.

[47]  W. Burman,et al.  Therapeutic implications of drug interactions in the treatment of human immunodeficiency virus-related tuberculosis. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[48]  M. Rowland,et al.  An outbreak of cutaneous leishmaniasis in an Afghan refugee settlement in north-west Pakistan. , 1999, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[49]  H. Noyes,et al.  A Nested-PCR-Based Schizodeme Method for Identifying Leishmania Kinetoplast Minicircle Classes Directly from Clinical Samples and Its Application to the Study of the Epidemiology of Leishmania tropica in Pakistan , 1998, Journal of Clinical Microbiology.

[50]  S. Croft,et al.  Failure of buparvaquone (Butalex) in the treatment of canine visceral leishmaniosis. , 1998, Veterinary parasitology.